Cancer Clinical Trials

A great benefit of our formal affiliation with the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is the local access to clinical trials. Our research team carefully screens all new oncology patients and attends all tumor board meetings to identify potential patients who might benefit from a study.

The number of available trials continues to grow. Please contact our clinical research nurse at 443-643-1181 for additional information.

A meeting explaining the trial, or clinical trials in general, can help you decide whether or not you would like to participate in the study. Participation is voluntary and you may stop at any time, for any reason. By agreeing to take part in a research study, you may need to see the doctor more often and you may also be required to have specific blood work or imaging completed. Frequent monitoring is done throughout the study to ensure safety.

Visit UM Cancer Network to learn more about this partnership.

General Cancer Trials

Currently nothing available.

Breast Cancer Trials

NRG–BR003 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (ClinicalTrials.gov NCT #02488967)

• Principal Investigator: Ashkan Bahrani, MD

GCC–1366 | A Prospective Study of Neoadjuvant Non-steroidal Aromatase Inhibitors in Postmenopausal Women with Operable Hormone Receptor-Positive Breast Cancer to Evaluate the Anti-proliferative Response in Obese and Overweight Patients (ClinicalTrials.gov NCT #02095184) 

• Principal Investigator: Suliat Nurudeen, MD, MPH

S1501 | Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III (ClinicalTrials.gov NCT #03418961)

• Principal Investigator: Ashkan Bahrani, MD

• Principal Investigator: Ashkan Bahrani, MD

S2010 | A randomized, Phase III trial comparing active symptom monitory plus patient education versus patient education alone to improve persistence with endocrine therapy in young women with Stage I - Stage III Breast Cancer 

• Principal Investigator: Ashkan Bahrani, MD

HP-98661 | The effects of exercise and nutrition interventions on chemotherapy-induced peripheral neuropathy and interoceptive brain circuitry.

• Principal Investigator: Ian Kleckner, PhD, MPH

Head and Neck Cancer Trials

EA3161 | A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC (ClinicalTrials.gov NCT #03811015) 

• Principal Investigator: Ashkan Bahrani, MD

Colorectal Cancer Trials

A221805 | Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II to Phase III Study (ClinicalTrials.gov NCT #04137107)

• Principal Investigator: Ashkan Bahrani, MD

NRG–GI005 | Phase II/III study of Circulating Tumor DNA as a predictive Biomaker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA) (ClinicalTrials.gov NCT #04068103)

• Principal Investigator: Ashkan Bahrani, MD

NRG–GI008 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (ClinicalTrials.gov NCT #05174169)

• Principal Investigator: Ashkan Bahrani, MD

HP-98661 | The effects of exercise and nutrition interventions on chemotherapy-induced peripheral neuropathy and interoceptive brain circuitry.

• Principal Investigator: Ian Kleckner, PhD, MPH

Lung Cancer Trials

LUNG-MAP | A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (ClinicalTrials.gov NCT #03851445)

• Principal Investigator: Ashkan Bahrani, MD

A151216 | (Screening Trial) ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ClinicalTrials.gov NCT #02194738)

• Principal Investigator: Ashkan Bahrani, MD

E4512 | (ALCHEMIST Treatment Trial): A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ClinicalTrials.gov NCT #02201992)

• Principal Investigator: Ashkan Bahrani, MD

• Principal Investigator: Ashkan Bahrani, MD

EA5181 | Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (ClinicalTrials.gov NCT #04092283)

• Principal Investigator: Ashkan Bahrani, MD

Blood and Lymphatic System Disorder Trials

NHLBI-MDS | The National Myelodysplastic Syndromes Natural History Study (ClinicalTrials.gov NCT #02775383)

• Principal Investigator: Ashkan Bahrani, MD

FREDA | Time-restricted eating to address persistent cancer-related fatigue: The Fatigue Reduction After Cancer (FREDA) trial (ClinicalTrials.gov NCT #05256888)

• Principal Investigator: Amber Kleckner, PhD

NRG-CC010 | A Phase III trial of the impact of sentinel lymph node mapping on patient reported lower extremity limb dysfunction in endometrial cancer (ClinicalTrials.gov NCT #00956670) 

• Principal Investigator: Guatam G. Rao, MD

Repository: Multi-Site Tissue and Biofluid Banking Trials

AST-FPB-US | A Multi-Center Study for the Collection of Surplus Surgical Tissues for Genomics, Proteomics and Biomarker Research (Fresh, Preserved, Biofluid)

• Principal Investigator: Vernon King, MD

MTG-015 | Tissue and Bodily Fluids. Discovery and Evaluation of Biomarkers for the Diagnosis and Treatment of Disease

• Principal Investigator: Vernon King, MD

Quality of Life Studies

Maryland Living Well, Cancer: Thriving and Surviving QOL Research | Maryland Department on Aging, Maryland Department of Health and Mental Hygiene